Medications as a potential source of exposure to phthalates in the U.S. population

DSpace/Manakin Repository

Medications as a potential source of exposure to phthalates in the U.S. population

Citable link to this page

. . . . . .

Title: Medications as a potential source of exposure to phthalates in the U.S. population
Author: Kelley, Katherine E.; Calafat, Antonia M.; Mitchell, Allen Avrom; Hauser, Russ B.; Hernández-Díaz, Sonia

Note: Order does not necessarily reflect citation order of authors.

Citation: Hernández-Díaz, Sonia, Allen A. Mitchell, Katherine E. Kelley, Antonia M. Calafat, and Russ Hauser. 2009. Medications as a potential source of exposure to phthalates in the U.S. population. Environmental Health Perspectives 117(2): 185-189.
Full Text & Related Files:
Abstract: Background: Widespread human exposure to phthalates, some of which are developmental and reproductive toxicants in experimental animals, raises concerns about potential human health risks. Underappreciated sources of exposure include phthalates in the polymers coating some oral medications. Objective: The objective of this study was to evaluate whether users of phthalate-containing medications have higher urinary concentrations of phthalate metabolites than do nonusers. Methods: We used publically available files from the National Health and Nutrition Examination Survey for the years 1999–2004. For certain survey periods, participants were asked to recall use of prescription medication during the past 30 days, and for a subsample of individuals, the urinary concentrations of phthalate metabolites were measured. We a priori identified medications potentially containing phthalates as inactive ingredients and then compared the mean urinary concentration of phthalate metabolites between users and nonusers of those medications. Results: Of the 7,999 persons with information on urinary phthalate concentrations, 6 reported using mesalamine formulations, some of which may include dibutyl phthalate (DBP); the mean urinary concentration of monobutyl phthalate, the main DBP metabolite, among these mesalamine users was 50 times higher than the mean for nonusers (2,257 μg/L vs. 46 μg/L; p < 0.0001). Users of didanosine, omeprazole, and theophylline products, some of which may contain diethyl phthalate (DEP), had mean urinary concentrations of monoethyl phthalate, the main DEP metabolite, significantly higher than the mean for nonusers. Conclusion: Select medications might be a source of high exposure to some phthalates, one of which, DBP, shows adverse developmental and reproductive effects in laboratory animals. These results raise concern about potential human health risks, specifically among vulnerable segments of the general population and particularly pregnant women and children.
Published Version: doi:10.1289/ehp.11766
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2649218/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4888657

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters